NCT06510751 Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P
| NCT ID | NCT06510751 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Melike Cengiz |
| Condition | Meningitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 51 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2025-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 51 participants in total. It began in 2024-03-01 with a primary completion date of 2025-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In cases of meningitis caused by external ventricular catheters (EVDs), which are the most commonly placed intracranial catheters that can lead to central nervous system infection through contamination/colonisation, the diagnosis may not be differentiated by either clinical signs and symptoms or conventional cerebrospinal fluid (CSF) tests. Therefore, due to the limitations in diagnosis and prognostic prediction of EVD-induced meningitis and the high mortality/morbidity rates of the disease, markers with high sensitivity and specificity in post-operative meningitis are needed. Calcitonin gene-related peptide (CGRP), a neuropeptide, has been shown to increase when C or Aδ sensory fibres are damaged or in the presence of inflammation in tissues adjacent to the fibres. CGRP is localised in nociceptive nerve terminals together with another neuropeptide, substance P, which has similar biological effects. There are very few studies investigating how CGRP levels in CSF and serum change in bacterial meningitis. Although it is thought that nociception and neuroimmune interactions affect meningeal antibacterial host defence, that nociceptors signal via CGRP to meningeal immune cells during infection, and that this neuroimmune axis exacerbates bacterial meningitis by weakening host defence, it is not yet clear how CGRP and substance P levels affect disease prognosis. This study will evaluate the utility of CGRP and substance P levels as biomarkers to assess diagnosis and treatment response in patients with post-operative meningitis followed in the intensive care unit.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years and over * Patients followed up in the intensive care unit with suspected meningitis Exclusion Criteria: * Patients under 18 years of age * Patients with suspected meningitis in the intensive care unit who have not undergone neurosurgical operation and do not have CSF drainage catheter
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06510751 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Meningitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06510751 currently recruiting?
Yes, NCT06510751 is actively recruiting participants. Contact the research team at melikecengiz@yahoo.com for enrollment information.
Where is the NCT06510751 trial being conducted?
This trial is being conducted at Antalya, Turkey (Türkiye).
Who is sponsoring the NCT06510751 clinical trial?
NCT06510751 is sponsored by Melike Cengiz. The trial plans to enroll 51 participants.